Medindia
Browse this site with No Ads Click Here
Medindia » Health In Focus

L-glutamine Approved for Sickle Cell Disease

by Simi Paknikar on July 10, 2017 at 4:25 PM
Listen to this News

Highlights:

The U.S. Food and Drug Administration (FDA) has approved the use of an oral powder formulation of L-glutamine for the treatment of sickle cell disease.


Sickle cell disease is a genetic condition that affects the hemoglobin in red blood cells. Hemoglobin is a pigment which gives the blood its red color. It picks up oxygen from the lungs and carries it to various parts of the body, and also carries carbon dioxide in the reverse direction.

‘L-glutamine has recently received FDA approval for the treatment of sickle cell disease.’

Patients with sickle cell disease have abnormal hemoglobin. If the oxygen levels are low, the disc-shaped red blood cells assume a sickle shaped. The shape does not allow them to pass through blood vessels easily and they can therefore obstruct the flow of blood to various organs. Patients suffer from frequent severe painful episodes, which often require painkiller injections. The cells also have a tendency to break, as a result of which anemia ensues. Currently, hematopoietic stem cell transplant is the definitive treatment for sickle cell disease, though it may be beyond the reach of several patients.

A medication called hydroxyurea is used for the treatment of sickle cell disease. It increases the levels of a type of hemoglobin called fetal hemoglobin, and therefore reduces the complications of sickle cell disease.

Studies found that the red blood cells affected by sickle cell disease are under high oxidative stress and try to protect themselves by producing a chemical called nicotinamide adenine dinucleotide (NAD) molecules. The newly approved drug, l-glutamine, is an amino acid required to produce NAD molecules, and can therefore protect the red blood cells.

L-glutamine can be taken as an oral powder by sickle cell disease patients as young as 5 years of age. The approval comes following the results of a trial, which compared the use of L-glutamine to a placebo taken for a duration of 48 weeks. The participants of the trial had previously suffered at least two attacks of painful crises in the previous year. The patients who took the medication had:

The side effects of l-glutamine noted in the study included constipation, nausea, headache, abdominal pain, cough, pain in the extremities, back pain and chest pain.

The new drug will hopefully be a boon to several patients affected by sickle cell disease.

References:

  1. FDA approves new treatment for sickle cell disease - (https:www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm566084.htm)
  2. What is Sickle Cell Disease - (https:www.nhlbi.nih.gov/health/health-topics/topics/sca)
  3. Niihara Y, Macan H, Eckman JR, Koh H, Cooper ML, et al. (2014) L-Glutamine Therapy Reduces Hospitalization for Sickle Cell Anemia and Sickle β�-Thalassemia Patients at Six Months - A Phase II Randomized Trial. Clin Pharmacol Biopharm 3:116. doi:10.4172/2167-065X.1000116
Source: Medindia

Cite this Article

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Simi Paknikar. (2017, July 10). L-glutamine Approved for Sickle Cell Disease. Medindia. Retrieved on Oct 10, 2024 from https://www.medindia.net/news/healthinfocus/l-glutamine-approved-for-sickle-cell-disease-171558-1.htm.

  • MLA

    Simi Paknikar. "L-glutamine Approved for Sickle Cell Disease". Medindia. Oct 10, 2024. <https://www.medindia.net/news/healthinfocus/l-glutamine-approved-for-sickle-cell-disease-171558-1.htm>.

  • Chicago

    Simi Paknikar. "L-glutamine Approved for Sickle Cell Disease". Medindia. https://www.medindia.net/news/healthinfocus/l-glutamine-approved-for-sickle-cell-disease-171558-1.htm. (accessed Oct 10, 2024).

  • Harvard

    Simi Paknikar. 2017. L-glutamine Approved for Sickle Cell Disease. Medindia, viewed Oct 10, 2024, https://www.medindia.net/news/healthinfocus/l-glutamine-approved-for-sickle-cell-disease-171558-1.htm.

View Non AMP Site | Back to top ↑